<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="available evidence including the conventional 21/7 combined hormonal contraception, the" exact="desogestrel" post="only oral pill, combined oral contraceptives with shortened pill-free"/>
 <result pre="oral contraceptives with shortened pill-free interval, combined oral contraceptives with" exact="estradiol" post="supplementation during the pill-free interval, extended regimen of combined"/>
 <result pre="with pill or patch, combined hormonal contraceptive vaginal ring, transdermal" exact="estradiol" post="supplementation with gel, transdermal estradiol supplementation with patch, subcutaneous"/>
 <result pre="hormonal contraceptive vaginal ring, transdermal estradiol supplementation with gel, transdermal" exact="estradiol" post="supplementation with patch, subcutaneous estrogen implant with cyclical oral"/>
 <result pre="of new treatments for migraine prevention which act on the" exact="calcitonin" post="gene-related peptide (CGRP) pathway. This offsets the lack of"/>
 <result pre="have success in its treatment, and inflammatory molecules such as" exact="nitric oxide," post="CGRP, and cytokines are able to recreate migraine pain."/>
 <result pre="University Hospital, Glostrup, Denmark. Correspondence: Lars Edvinsson (lars.edvinsson@med.lu.se) Background. The" exact="calcitonin" post="gene-related peptide (CGRP) family of neuropeptides consists besides CGRP"/>
 <result pre="family of neuropeptides consists besides CGRP of adrenomedullin, amylin and" exact="calcitonin" post="(CT). They share receptor components and structure, and have"/>
 <result pre="have several similar biological actions. The receptors consist of either" exact="calcitonin" post="receptor like-receptor (CLR) or calcitonin receptor (CTR) which for"/>
 <result pre="The receptors consist of either calcitonin receptor like-receptor (CLR) or" exact="calcitonin" post="receptor (CTR) which for function needs an accessory protein,"/>
 <result pre="progestogen-only methods (progestogen-only pill [POP], subdermal implant [SDI], intramuscular/subcutaneous depot" exact="medroxyprogesterone" post="acetate [DMPA], and levonorgestrel intrauterine system [LNG-IUS]), all of"/>
 <result pre="[POP], subdermal implant [SDI], intramuscular/subcutaneous depot medroxyprogesterone acetate [DMPA], and" exact="levonorgestrel" post="intrauterine system [LNG-IUS]), all of which, with the exception"/>
 <result pre="recruited follicles undergo atresia, resulting in a drop in endogenous" exact="estradiol" post="levels. Continuous or extended regimens with a shorted CFI"/>
 <result pre="to reduce the frequency and severity of estrogen-withdrawal symptoms. The" exact="desogestrel" post="POP and implant inhibit ovulation but do not predictably"/>
 <result pre="Guidelines. Previous (2014) European recommendations on limiting the use of" exact="valproate" post="in women of childbearing age did not achieve their"/>
 <result pre="achieve their objective in terms of limiting the use of" exact="valproate" post="in women of child bearing age and raising awareness"/>
 <result pre="bearing age and raising awareness regarding the hazardous effect of" exact="valproate" post="to children exposed in utero. The teratogenic and foetotoxic"/>
 <result pre="children exposed in utero. The teratogenic and foetotoxic effects of" exact="valproate" post="are well documented, and more recent studies show that"/>
 <result pre="is an even greater neurodevelopmental risk to children exposed to" exact="valproate" post="in the womb. The latest 2018 European review from"/>
 <result pre="the observations leading to the development of lisinioril and later" exact="candesartan" post="as migraine prophylactics. The large epidemiological survey in Nord-Trøndelag"/>
 <result pre="In susceptible individuals, the trigeminovascular neurons release neurotransmitters, such as" exact="calcitonin" post="gene-related peptide and substance P, when headache triggers are"/>
 <result pre="Savino A. Epidural blood patch in Trendelenburg position pre–medicated with" exact="acetazolamide" post="to treat spontaneous intracranial hypotension. Eur J Neurol 2010,"/>
 <result pre="to worsen the comorbid psychiatric disorder should be avoided (i.e." exact="topiramate" post="in migraine and depression). Drugs able to control both"/>
 <result pre="control both disorders, possibly in monotherapy, should be preferred (i.e." exact="propranolol" post="in migraine and mild anxiety). The migraine treatment plan"/>
 <result pre="is high interest in blocking the actions of the neuropeptide" exact="calcitonin" post="gene-related peptide (CGRP) for the treatment of migraine and"/>
 <result pre="efforts have focussed on the canonical CGRP receptor, comprising the" exact="calcitonin" post="receptor-like receptor (CLR) with receptor activity-modifying protein 1 (RAMP1)."/>
 <result pre="1 receptor, which is a complex of RAMP1 with the" exact="calcitonin" post="receptor (CTR). Very few studies have directly compared the"/>
 <result pre="activation of the trigemino-autonomic reflex of which the vasoactive peptides" exact="calcitonin" post="gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) and pituitary"/>
 <result pre="Galcanezumab, a humanised monoclonal antibody that selectively binds to the" exact="calcitonin" post="gene-related peptide, was superior to placebo in the prevention"/>
 <result pre="of galcanezumab, a humanized monoclonal antibody that selectively binds to" exact="calcitonin" post="gene-related peptide (CGRP), in individuals with episodic cluster headache."/>
 <result pre="in the final analysis. Eleven patients treated their migraine with" exact="sumatriptan" post="while the remaining 15 patients did not treat their"/>
 <result pre="a meningeal site of migraine headache. O11 Migraine induction with" exact="calcitonin" post="gene-related peptide in patients from erenumab trials Casper Emil"/>
 <result pre="Food and Drug Administration as a monoclonal antibody against the" exact="calcitonin" post="gene-related peptide (CGRP) receptor for migraine-specific preventive treatment. Identifying"/>
 <result pre="methylation in migraine. Several studies have shown that the neuropeptide" exact="calcitonin" post="gene–related peptide (CGRP), encoded by CALCA gene, has a"/>
 <result pre="USA Background Galcanezumab (GMB) is a humanised monoclonal antibody against" exact="calcitonin" post="gene-related peptide under development for prevention of migraine. Objective"/>
 <result pre="Susan P. Mollan (susan.mollan@uhb.nhs.uk) Introduction: The efficacy and safety of" exact="tocilizumab" post="(TCZ), an IL-6 receptor-α inhibitor, was evaluated in patients"/>
 <result pre="reactant elevation attributable to GCA. Randomization was stratified by baseline" exact="prednisone" post="dose (≤30 or &amp;gt;30 mg/day) as selected by the"/>
 <result pre="(20-60 mg/day). Patients were randomized 1:1:2:1 to 4 groups: short-course" exact="prednisone" post="(SCP) or long-course prednisone (LCP) (26-week or 52-week prednisone"/>
 <result pre="randomized 1:1:2:1 to 4 groups: short-course prednisone (SCP) or long-course" exact="prednisone" post="(LCP) (26-week or 52-week prednisone taper + weekly subcutaneous"/>
 <result pre="short-course prednisone (SCP) or long-course prednisone (LCP) (26-week or 52-week" exact="prednisone" post="taper + weekly subcutaneous [SC] placebo, respectively); or weekly"/>
 <result pre="every other week (TCZ-Q2W) SC TCZ 162 mg + 26-week" exact="prednisone" post="taper. Prednisone doses &amp;lt;20 mg/day were blinded. Patients who"/>
 <result pre="could not adhere to the protocol-defined tapering schedule received open-label" exact="prednisone" post="escape therapy but continued on double-blind TCZ/placebo. Sustained remission"/>
 <result pre="C-reactive protein after week 12, and adherence to the protocol-defined" exact="prednisone" post="taper. The primary and key secondary endpoint was the"/>
 <result pre="deaths or new vision loss occurred. Conclusion: TCZ plus 26-week" exact="prednisone" post="taper was superior to SCP and LCP tapers for"/>
 <result pre="LCP tapers for sustained remission at 52 weeks. TCZ plus" exact="prednisone" post="also led to a substantial reduction in the cumulative"/>
 <result pre="prednisone also led to a substantial reduction in the cumulative" exact="prednisone" post="doses required to control GCA. Trial registration: NCT01791153 /"/>
 <result pre="medications available. Galcanezumab, a humanized monoclonal antibody that binds to" exact="calcitonin" post="gene-related peptide (CGRP), was developed for the prevention of"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), is efficacious in preventing EM, but"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), is efficacious in preventing chronic migraine"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has been shown to be effective"/>
 <result pre=". In regards to preventive treatment choice; in chronic migraine" exact="topiramate" post="(57%) amytriptiline (17.9%) and beta-blockers (14.6%), whereas in episodic"/>
 <result pre="whereas in episodic migraine the preferred drugs were beta-blockers (47.7%)," exact="topiramate" post="(21.5%) and amytriptiline (13.4%). Regarding perceived efficacy, topiramate was"/>
 <result pre="beta-blockers (47.7%), topiramate (21.5%) and amytriptiline (13.4%). Regarding perceived efficacy," exact="topiramate" post="was considered the best option in chronic migraine (42.7%)"/>
 <result pre="onabotulinumtoxinA (25.5%) and amitryptiline (22.4%). In episodic migraine, neurologist preferred" exact="topiramate" post="(43.7%) and beta-blockers (30.3%). Regarding the duration of preventive"/>
 <result pre="the most effective therapy. O43 Effect of the H 1-antihistamine" exact="clemastine" post="on PACAP38 induced migraine Luise Haulund Vollesen 1, Song"/>
 <result pre="(ashina@dadlnet.dk) Objective To investigate the effect of the H 1-antihistamine" exact="clemastine" post="on the migraine inducing abilities of pituitary adenylate cyclase"/>
 <result pre="migraine without aura patients were randomly allocated to receive bolus" exact="clemastine" post="2 mg (1 mg/ml) or bolus saline 2 ml"/>
 <result pre="factor-alpha (TNF-alpha) before and after infusion of PACAP38. Results After" exact="clemastine" post="pretreatment 5/20 participants developed a migraine-like attack in response"/>
 <result pre="PACAP38 infusion compared to 9/20 after placebo pretreatment (P=0.288). Following" exact="clemastine" post="pretreatment 15/20 participants reported headache in response to a"/>
 <result pre="tryptase (P = 0.525) or TNF-alpha (P = 0.487) between" exact="clemastine" post="and placebo pretreatment days. Conclusion H1-antihistamine, clemastine, failed to"/>
 <result pre="Neurol 2017;264:1023-8. O47 Association of Tanacethum Parthenium, 5 - hydroxy" exact="tryptophan" post="and magnesium ( Aurastop) versus Mg tablet impact on"/>
 <result pre="phytotherapic combination of Tanacethum Parthenium (150 mg), 5 - hydroxy" exact="tryptophan" post="(20 mg) and magnesium (185 mg) (Aurastop ®) is"/>
 <result pre="disability of the combination of Tanacethum Parthenium, 5 - hydroxy" exact="tryptophan" post="and magnesium versus magnesium alone, when taken at the"/>
 <result pre="the next two days there was complete relief with oral" exact="indomethacin" post="200 mg per day and an improvement of the"/>
 <result pre="found in DWI sequences . The patient was started on" exact="acetylsalicylic acid" post="100 mg daily. An extended CT angiography showed extensive"/>
 <result pre="syndrome. The history of cluster headache, a specific response to" exact="indomethacin" post="and the absence of neurological focal signs does not"/>
 <result pre="treatments, they were effective in 69% of patients. Pregabalin and" exact="amitriptyline" post="were the most effective prophylaxis therapies (in 80% and"/>
 <result pre="quality and intensity of pain are highly heterogeneous, whereas NSAIDs," exact="pregabalin" post="and amitriptyline were the most prescribed and effective therapies."/>
 <result pre="intensity of pain are highly heterogeneous, whereas NSAIDs, pregabalin and" exact="amitriptyline" post="were the most prescribed and effective therapies. Ethics approval"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), reduced the number of migraine days"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), reduced the frequency and severity of"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in preventing episodic"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has been shown to be effective"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention."/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention."/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention."/>
 <result pre="OBJECTIVES: The long-term efficacy of monoclonal antibodies that selectively target" exact="calcitonin" post="gene-related peptide (CGRP) in patients with early treatment failure"/>
 <result pre="Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets" exact="calcitonin" post="gene-related peptide (CGRP), reduced the frequency and severity of"/>
 <result pre="release a number of vasodilatory and cytoprotective mediators, including the" exact="calcitonin" post="gene-related peptide (CGRP). Erenumab, a fully human anti-CGRP receptor"/>
 <result pre="Stauffer (stauffer_virginia@lilly.com) Objective: Galcanezumab, a humanized monoclonal antibody that binds" exact="calcitonin" post="gene-related peptide, has a half-life of 27 days so"/>
 <result pre="profile of galcanezumab, a humanized monoclonal antibody that selectively binds" exact="calcitonin" post="gene-related peptide (CGRP) and inhibits its activity, in patients"/>
 <result pre="duration, Headache frequency, Migraine, Visual Analog Scale P29 Effect of" exact="propranolol" post="in a non-invasive human model of trigeminovascular activation Eloísa"/>
 <result pre="migraine since many years. However, the mechanism of action of" exact="propranolol" post="in preventing migraine attacks has not yet been elucidated."/>
 <result pre="suggested. In our study, we set out to assess whether" exact="propranolol" post="has an inhibitory effect on the trigeminovascular system in"/>
 <result pre="our human forehead perfusion model. We investigated the effect of" exact="propranolol" post="(80 mg, 90 min after oral administration, corresponding to"/>
 <result pre="electrical stimulation(0.2-1.0 mA) before and after placebo (grapefruit juice) and" exact="propranolol" post="(oral solution with tangerine taste, diluted in grapefruit juice)"/>
 <result pre="DBF responses to capsaicin (mean±SEM: 512.72±33.14 A.U.) were attenuated after" exact="propranolol" post="(mean±SEM: 465.67±35.12 A.U., p&amp;lt;0.05) but no after placebo (mean±SEM:"/>
 <result pre="by either placebo or propranolol. When sexes were analyzed separately," exact="propranolol" post="had no effect on the DBF responses to capsaicin"/>
 <result pre="males (mean±SEM: 472±54.57 A.U. vs. 394.7±51.09 A.U.; p&amp;lt;0.05). In conclusion," exact="propranolol" post="80 mg inhibits the capsaicin-induced increases in DBF, suggesting"/>
 <result pre="days was reported by two patients. In the second study," exact="sumatriptan" post="25 mg 4 doses/day resulted superior to placebo in"/>
 <result pre="40: 316-319. 6. Hodgson C, Roiberg-Henry A. The use of" exact="sumatriptan" post="in the treatment of postdural headache. Anaesthesia 1997; 52:"/>
 <result pre="Anaesthesia 1996; 51: 1078. 8. Sprigge JS. The use of" exact="sumatriptan" post="in the treatment of postdural puncture headache after accidental"/>
 <result pre="31-year-old woman presented with thunderclap headache after 1 week of" exact="paroxetine" post="and alprazolam treatment due to new onset psychiatric symptoms."/>
 <result pre="presented with thunderclap headache after 1 week of paroxetine and" exact="alprazolam" post="treatment due to new onset psychiatric symptoms. Brain MRI"/>
 <result pre="interleukin 6 (IL-6), interleukin 10 (IL-10), high-sensitivity C-reactive protein (hs-CRP)," exact="calcitonin" post="gene-related peptide (CGRP); endothelial dysfunction: pentraxin 3 (PTX3), soluble"/>
 <result pre="to episodic migraine with erenumab, a specific inhibitor of the" exact="calcitonin" post="gene-related peptide receptor Richard B. Lipton 1, Stewart J."/>
 <result pre="a fully human monoclonal antibody that specifically inhibits the canonical" exact="calcitonin" post="gene-related peptide receptor and was developed as a preventive"/>
 <result pre="analgesics or ≥10 days/month on triptans, combination of therapies, or" exact="ergotamine" post="derivatives). The objective of this study was to evaluate"/>
 <result pre="the rat evoked by recurrent administration of systemic administration of" exact="isosorbide dinitrate" post="(ISDN), a nitric oxide donor (NO). Recurrent ISDN injection"/>
 <result pre="recurrent administration of systemic administration of isosorbide dinitrate (ISDN), a" exact="nitric oxide" post="donor (NO). Recurrent ISDN injection (10 mg/kg, i.p., 5"/>
 <result pre="patients. Average of headache attack / day: 5.7, main sc" exact="sumatriptan" post="/ day consumption: 4.4. Efficacy of NOM-S: 50%. NOM-S"/>
 <result pre="then. Average of headache attack / day: 6.5, mean sc" exact="sumatriptan" post="/ day consumption: 5.7. Efficacy: 85.7%. DBS reduced NRS"/>
 <result pre="ADM_12 was able to abolish the increased levels of TRPA1," exact="calcitonin" post="gene-related peptide (CGRP) and substance P (SP) gene expression"/>
 <result pre="in the final analysis. Eleven patients treated their migraine with" exact="sumatriptan" post="while the remaining 15 patients did not treat their"/>
 <result pre="A multicenter, prospective, randomized, open-label study to compare onabotulinumtoxinA and" exact="topiramate" post="for headache prevention in adults with chronic migraine: patient"/>
 <result pre="world effectiveness. Safety, tolerability, and PROs of onabotulinumtoxinA (onabotA) vs" exact="topiramate" post="(TPM) for CM are presented. Methods: FORWARD, a multicenter,"/>
 <result pre="drug concentration (C max, ng/ml) were found only for frovatriptan," exact="zolmitriptan" post="and rizatriptan. Women appeared to have a higher AUC"/>
 <result pre="differences were revealed on plasma half-life Times (T 1/2) of" exact="frovatriptan" post="(2 studies, RoM 0.90, CI: 0.70-1.14) and zolmitriptan (8"/>
 <result pre="1/2) of frovatriptan (2 studies, RoM 0.90, CI: 0.70-1.14) and" exact="zolmitriptan" post="(8 studies, RoM 0.93, CI: 0.85-1.01). Conclusions Given the"/>
 <result pre="max are higher in women than in men for frovatriptan," exact="zolmitriptan" post="and rizatriptan, which may be an explanation for the"/>
 <result pre="plots of AUC0-∞ and Cmax after the intake of frovatriptan," exact="rizatriptan" post="or zolmitriptan in male and female migraine patients. P86"/>
 <result pre="AUC0-∞ and Cmax after the intake of frovatriptan, rizatriptan or" exact="zolmitriptan" post="in male and female migraine patients. P86 Migraine induction"/>
 <result pre="in male and female migraine patients. P86 Migraine induction with" exact="calcitonin" post="gene-related peptide in patients from erenumab trials Casper Emil"/>
 <result pre="Food and Drug Administration as a monoclonal antibody against the" exact="calcitonin" post="gene-related peptide (CGRP) receptor for migraine-specific preventive treatment. Identifying"/>
 <result pre="education. The most commonly overused medication was multi-therapy (acetylsalicylic acid," exact="acetaminophen" post="and caffeine) among the population. Conclusion. The prevalence of"/>
 <result pre="(31%). For the treatment of migraine the preferred option was" exact="paracetamol" post="(47,6%) followed by NSAID (9,5%). Conclusions: Despite headache is"/>
 <result pre="is a fully human monoclonal antibody (mAb) targeting the canonical" exact="calcitonin" post="gene-related peptide (CGRP) receptor [2]. The objective of this"/>
 <result pre="We administered an intravenous (IV) cocktail consisting of ketorolac, Compazine," exact="diphenhydramine" post="and 20mg/kg bolus of normal saline. The infusion was"/>
 <result pre="(8-14 HD), and 36% (15+HD) received preventive treatment. Sumatriptan and" exact="ibuprofen" post="were the most commonly prescribed acute treatments across all"/>
 <result pre="commonly prescribed acute treatments across all headache frequency categories, while" exact="metoprolol" post="and topiramate were the most frequently prescribed preventive treatments."/>
 <result pre="acute treatments across all headache frequency categories, while metoprolol and" exact="topiramate" post="were the most frequently prescribed preventive treatments. Over the"/>
 <result pre="patients based on duration of remissions. Increased blood levels of" exact="calcitonin" post="gene-related peptide (CGRP) have been associated with CH, making"/>
 <result pre="15.5 hours. The proportion of patients using oxygen and/or subcutaneous" exact="sumatriptan" post="during the prospective baseline period was 45.3% and 56.6%,"/>
 <result pre="and acute therapy to stop the attack. Although amitriptyline, topiramate," exact="flunarizine" post="and valproic acid have the most data on their"/>
 <result pre="therapy to stop the attack. Although amitriptyline, topiramate, flunarizine and" exact="valproic acid" post="have the most data on their use for prophylaxis"/>
 <result pre="D., Lavano, A., 2016. Administration of palmitoylethanolamide in combination with" exact="topiramate" post="in the preventive treatment of nummular headache. International medical"/>
 <result pre="applicable P130 Efficient therapy for treatment of migraine without aura:" exact="ergotamine" post="based drugs or sumatriptan Sinisa Miljkovic 1, Dz. Smajlovic"/>
 <result pre="for treatment of migraine without aura: ergotamine based drugs or" exact="sumatriptan" post="Sinisa Miljkovic 1, Dz. Smajlovic 2, S. Crncevic 1,"/>
 <result pre="Neurology, Bosnia and Herzegovina Correspondence: Sinisa Miljkovic (sinisa.miljkovic@kc-bl.com) Background: Triptans," exact="ergotamine" post="and dihydroergotamine are the most effective medications in the"/>
 <result pre="and Herzegovina Correspondence: Sinisa Miljkovic (sinisa.miljkovic@kc-bl.com) Background: Triptans, ergotamine and" exact="dihydroergotamine" post="are the most effective medications in the treatment of"/>
 <result pre="to one of the two study groups - Nomigren® or" exact="sumatriptan" post="group. Diagnosis was based on International Headache Society Criteria"/>
 <result pre="51.12% attacks in Nomigren® group, and in 33.70% attacks in" exact="sumatriptan" post="group (p=0.0015). Nomigren® has shown equally sustainable high efficiency"/>
 <result pre="in repeated attacks in Nomigren® group was 50.91%, and in" exact="sumatriptan" post="group it was 23.73% (p=0,005). Reversal of photophobia, phonophobia"/>
 <result pre="complete cessation of migraine pain and accompanying symptoms compared to" exact="sumatriptan" post="in the treatment of migraine without aura. P131 Analysis"/>
 <result pre="Objective: The humanized monoclonal antibody galcanezumab (LY2951742), which binds to" exact="calcitonin" post="gene-related peptide, has been evaluated for migraine prevention. The"/>
 <result pre="as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine," exact="calcitonin" post="gene-related peptide (CGRP) and response to triptans and neuromodulation."/>
 <result pre="a significant increase in the number of patients treated with" exact="oxcarbazepine" post="but there was no significant dosage increment of any"/>
 <result pre="2 (abstract P155). Topography of headache P156 Ibuprofen and not" exact="paracetamol" post="as first line analgesic for acute migraine due to"/>
 <result pre="acute migraine headache, many patients rely on over-the-counter analgesics. Both" exact="ibuprofen" post="and paracetamol are cornerstone therapies, without consensus on which"/>
 <result pre="headache, many patients rely on over-the-counter analgesics. Both ibuprofen and" exact="paracetamol" post="are cornerstone therapies, without consensus on which one is"/>
 <result pre="A recent overview of systematic reviews and meta-analyses directly compared" exact="ibuprofen" post="and paracetamol at standard doses and concluded that ibuprofen"/>
 <result pre="overview of systematic reviews and meta-analyses directly compared ibuprofen and" exact="paracetamol" post="at standard doses and concluded that ibuprofen was superior"/>
 <result pre="compared ibuprofen and paracetamol at standard doses and concluded that" exact="ibuprofen" post="was superior in relieving headache pain at two hours"/>
 <result pre="remains elusive. This study aimed to assess the effect of" exact="ibuprofen" post="and paracetamol on TRPA1, an ion channel implicated in"/>
 <result pre="This study aimed to assess the effect of ibuprofen and" exact="paracetamol" post="on TRPA1, an ion channel implicated in the pathophysiology"/>
 <result pre="healthy male volunteers were included to evaluate the effect of" exact="ibuprofen" post="(600 mg) and paracetamol (1 g) on TRPA1 in"/>
 <result pre="included to evaluate the effect of ibuprofen (600 mg) and" exact="paracetamol" post="(1 g) on TRPA1 in a randomized, double blind,"/>
 <result pre="a 60 minutes period (AUC 0-60min) following administration of ibuprofen," exact="paracetamol" post="or no drug was analyzed using one-way ANOVA with"/>
 <result pre="with post-hoc Bonferroni correction. Results: As shown in figure 1," exact="paracetamol" post="had no significant effect on the CA-induced DBF response"/>
 <result pre="CA-induced DBF response compared to no drug treatment, while after" exact="ibuprofen" post="administration this DBF response was clearly reduced (p &amp;lt;"/>
 <result pre="target engagement biomarker model, we demonstrated that the non-selective COX-inhibitor" exact="ibuprofen" post="reduces the DBF increase induced by CA. This possibly"/>
 <result pre="the DBF increase induced by CA. This possibly elucidates why" exact="ibuprofen" post="was found superior in reducing headache pain compared to"/>
 <result pre="Moore RA et al. Overview review: Comparative efficacy of oral" exact="ibuprofen" post="and paracetamol (acetaminophen) across acute and chronic pain conditions."/>
 <result pre="et al. Overview review: Comparative efficacy of oral ibuprofen and" exact="paracetamol" post="(acetaminophen) across acute and chronic pain conditions. Eur. J."/>
 <result pre="Eur. J. Pain 2015;19:1213–1223. Fig. 1 (abstract P156). Influence of" exact="paracetamol" post="and ibuprofen on the CA-induced DBF response (n ="/>
 <result pre="Pain 2015;19:1213–1223. Fig. 1 (abstract P156). Influence of paracetamol and" exact="ibuprofen" post="on the CA-induced DBF response (n = 16). One-way"/>
 <result pre="morning stiffness or loss of strength. For the medical treatment" exact="duloxetine" post="30 mg was given to the patient and the"/>
 <result pre="and severity of the pain was detected. The dose of" exact="flunarizine" post="was increased to 10 mg and the patient was"/>
 <result pre="in serotonin metabolism. Tryptophan is a precursor of serotonin. Once" exact="tryptophan" post="concentrations diminished, it results in a short-term drop in"/>
 <result pre="level. However, much uncertainty still exists about the association between" exact="tryptophan" post="and migraine. Regarding the importance of adequate tryptophan intake"/>
 <result pre="association between tryptophan and migraine. Regarding the importance of adequate" exact="tryptophan" post="intake in regulating serotonin hemostasis and subsequent effects on"/>
 <result pre="designed the current study to assess the relationship between dietary" exact="tryptophan" post="intake and migraine headache risk. Methods The migraine group"/>
 <result pre="in order to explore the relationship between migraine and dietary" exact="tryptophan" post="intake. Results The mean(SD) of the age of participants"/>
 <result pre="fat(g/d), and cholesterol(mg/d). the models showed significant inverse association between" exact="tryptophan" post="intake and migraine risk [(OR in the 3 rd"/>
 <result pre="based investigation of the migraine headache risk according to dietary" exact="tryptophan" post="intake. Our results showed that subjects who had a"/>
 <result pre="subjects who had a median intake of 0.90-1.15 grams of" exact="tryptophan" post="per day had a reduced odds of developing migraine"/>
 <result pre="g/d. These findings therefore highlighted that considering enough intake of" exact="tryptophan" post="rich foods such as milk, poultry, egg, seafood, soybeans,"/>
 <result pre="prevention of a combination of Tanacethum Parthenium, 5 - hydroxy" exact="tryptophan" post="and magnesium (Aurastop ©) Giorgio Dalla Volta, Paola Zavarise,"/>
 <result pre="the novel phytotherapic combination of Tanacethum Parthenium (150 mg), 5-hydroxy" exact="tryptophan" post="(20 mg) and magnesium (185 mg) (Aurastop ©) acts"/>
 <result pre="is a fully human monoclonal antibody that selectively inhibits the" exact="calcitonin" post="gene-related peptide (CGRP) receptor and is under investigation for"/>
 <result pre="two years the headache frequency has been &amp;gt;20 days/month, with" exact="indomethacin" post="overuse. Along this period, the patient underwent prophylactic treatment"/>
 <result pre="overuse. Along this period, the patient underwent prophylactic treatment with" exact="propranolol" post="and flunarizine, both ineffective. Detoxification with dexamethasone was prescribed,"/>
 <result pre="prophylactic treatment with propranolol and flunarizine, both ineffective. Detoxification with" exact="dexamethasone" post="was prescribed, along with prophylactic treatment with amitriptyline up"/>
 <result pre="Detoxification with dexamethasone was prescribed, along with prophylactic treatment with" exact="amitriptyline" post="up to 30 mg/days. This therapy, although well tolerated,"/>
 <result pre="coeruleus in a well-known animal model of migraine based on" exact="nitroglycerin" post="(NTG) administration. Methods - Here, we tested the potential"/>
 <result pre="neurogenic pain [1]. Migraine sufferers refractory to conventional therapies as" exact="topiramate" post="and amitriptyline, volunteered a treatment with selective cannabinoids. Method:"/>
 <result pre="males, 58 females, mean age 42,7±14,1SD) who choose to re-test" exact="amitriptyline" post="50 mg/day/orally. Drugs were increased starting from 20 and"/>
 <result pre="1. Menon S et al The effect of 1 mg" exact="folic acid" post="supplementation on clinical outcomes in female migraine with aura"/>
 <result pre="paracetamol) and showed only a partial and unsatisfactory improvement from" exact="pregabalin" post="and amitriptyline, which are effective in treatment of neuropathic"/>
 <result pre="to have had a satisfactory response to topical corticosteroid (intranasal" exact="fluticasone" post="spray): at 6 months follow-up the patient referred symptom"/>
 <result pre="and acute therapy to stop the attack. Although amitriptyline, topiramate," exact="flunarizine" post="and valproic acid have the most data on their"/>
 <result pre="therapy to stop the attack. Although amitriptyline, topiramate, flunarizine and" exact="valproic acid" post="have the most data on their use for prophylaxis"/>
 <result pre="D., Lavano, A., 2016. Administration of palmitoylethanolamide in combination with" exact="topiramate" post="in the preventive treatment of nummular headache. International medical"/>
 <result pre="exogenous, at the time of menstruation estrogen and / or" exact="progesterone" post="levels are not low, The &quot;uterine wound&quot;, with large"/>
 <result pre="to conventional therapies in other centres. Controls choose to re-test" exact="amitriptyline" post="50 mg/day/orally in a 15 days treatment. No patient"/>
 <result pre="6%THC-7.5%CBD fixed combination induceed 20 fold higher anti-allodynic effect versus" exact="amitriptyline" post="short treatment: THC-CBD run-in value 16.5±4.6 SD versus post-treatment"/>
 <result pre="treatment: THC-CBD run-in value 16.5±4.6 SD versus post-treatment 8.1±4.9SD p&amp;gt;0.00001," exact="amitriptyline" post="run–in value versus post-treatment values: 16.1±4.6 SD versus 12.07±4.02SD,"/>
 <result pre="(0-10) temples/forehead 8.4±1.2SD after run–in, 2.2±1.6SD after THC-CBD, 6.8±3.4SD after" exact="amitriptyline" post="p&amp;gt;0.00001. Side Effects of 6%THC-7.5%CBD: Somnolence: n=1, amitriptyline group"/>
 <result pre="6.8±3.4SD after amitriptyline p&amp;gt;0.00001. Side Effects of 6%THC-7.5%CBD: Somnolence: n=1," exact="amitriptyline" post="group n=2, withdrawal at discontinuation n=0. Conclusion Bediol-induced anti-allodynic"/>
</results>
